New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties

References

• Foye WO. Pharmacodynamic agents. In: Foye’s Principles of Medicinal Chemistry. Lemke TL, Williams DA, Roche VF, and Zito SW, eds. UK: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013:610.
   Google Scholar
• Pinder RM, Brogden RN, Speight TM, Avery GS. Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1977;13(6):401–421. doi:10.2165/00003495-197713060-00001.
   PubMed Web of Science ®Google Scholar
• Greenwood DT. International vivalan symposium; Animal pharmacology of viloxazine (Vivalan). J Int Med Res. 1975;3.
   Web of Science ®Google Scholar
• Carlier PR, Lo MM, Lo PC, et al. Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group. Bioorg Med Chem Lett. 1998;8(5):487–492. doi:10.1016/S0960-894X(98)00062-6.
   Web of Science ®Google Scholar
• Lippman W, Pugsley TA. Effects of viloxazine, an antidepressant agent, on biogenic amine uptake mechanisms and related activities. Can J Physiol Pharmacol. 1976;54(4):494–509. doi:10.1139/y76-069.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Evaluation of SPN-812 ER low dose in children with ADHD. Available from: https://clinicaltrials.gov/ct2/show/NCT03247530?term=NCT03247530&rank=1. 2018. Accessed October 16, 2017.
   Google Scholar
• Clinicaltrials.gov. Evaluation of SPN-812 ER low dose in adolescents with ADHD. Available from: https://clinicaltrials.gov/ct2/show/NCT03247517?term=NCT03247517&rank=1. Accessed October 16, 2017.
   Google Scholar
• Clinicaltrials.gov. Evaluation of SPN-812 ER high dose in children with ADHD. Available from: https://clinicaltrials.gov/ct2/show/NCT03247543?term=NCT03247543&rank=1. Accessed October 16, 2017.
   Google Scholar
• Nageye F, Cortese S. Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD. Expert Rev Neurother. 2019;19(7):707–717. doi:10.1080/14737175.2019.1628640.
   PubMed Web of Science ®Google Scholar
• Johnson JK, Liranso T, Saylor K, et al. A Phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (Extended-Release Viloxazine) in children with ADHD. J Atten Disord. 2020;24(2):348–358. doi:10.1177/1087054719836159.
   PubMed Web of Science ®Google Scholar
• Nasser A, Faison SL, Liranso T et al. An assessment of QTc effects with SPN-812 (Extended-Release Viloxazine) in healthy adults. Neuroscience Education Institute 15th Annual Congress; November 7–10, 2019; Colorado Springs, CO.
   Google Scholar
• Corona GL, Frattini P, Cucchi ML, et al. Viloxazine in depressed women: clinical response and cardiovascular effects. Int J Clin Pharmacol Ther Toxicol. 1987;25(6):322–327.
   Google Scholar
• Faraone SV. The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018;87:255–270. doi:10.1016/j.neubiorev.2018.02.001.
   PubMed Web of Science ®Google Scholar
• Green EA, Raj V, Shibao CA, et al. Effects of norepinephrine reuptake inhibition on postural tachycardia syndrome. J Am Heart Assoc. 2013;2(5):e000395. doi:10.1161/JAHA.113.000395.
   Web of Science ®Google Scholar
• Wong DT, Threlkeld PG, Best KL, Bymaster FP. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther. 1982;222(1):61–65.
   PubMed Web of Science ®Google Scholar
• Wong EH, Sonders MS, Amara SG, et al. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry. 2000;47(9):818–829. doi:10.1016/S0006-3223(99)00291-7.
   Web of Science ®Google Scholar
• Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699–711. doi:10.1016/S0893-133X(02)00346-9.
   PubMed Web of Science ®Google Scholar
• Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340(2–3):249–258. doi:10.1016/S0014-2999(97)01393-9.
   PubMed Web of Science ®Google Scholar
• Greenwood DT. Viloxazine and neurotransmitter function. Adv Biochem Psychopharmacol. 1982;31:287–300.
   Google Scholar
• Arnsten AF. The emerging neurobiology of attention deficit hyperactivity disorder: the key role of the prefrontal association cortex. J Pediatr. 2009;154(5):I–S43. doi:10.1016/j.jpeds.2009.01.018.
   Web of Science ®Google Scholar
• Volkow ND, Morales M. The brain on drugs: from reward to addiction. Cell. 2015;162(4):712–725. doi:10.1016/j.cell.2015.07.046.
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Zhang W, Carter PA, et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl). 2002;160(4):353–361. doi:10.1007/s00213-001-0986-x.
   PubMed Web of Science ®Google Scholar
• Li D, Kerns EH, edited by. Blood-Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs;2015. ISBN 978-1-118-78835-6 (hardback).
   Google Scholar
• Settimo L, Taylor D. Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets. J Psychopharmacol. 2018;32(1):96–104. doi:10.1177/0269881117742101.
   Web of Science ®Google Scholar
• Paxinos G. The Rat Brain in Stereotaxic Coordinates. 6th ed. Academic Press; 2007.
   Google Scholar
• STRATTERA®. Prescribing Information. Indianapolis, IN: Lilly USA, LLC; 2017.
   Google Scholar
• VYVANSE®. Prescribing Information. Lexington, MA: Shire US Inc; 2018.
   Google Scholar
• CONCERTA®. Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2017.
   Google Scholar
• Martin IL, Baker GB, Mitchell PR. The effect of viloxazine hydrochloride on the transport of noradrenaline, dopamine, 5-hydroxytryptamine and gamma-amino-butyric acid in rat brain tissue. Neuropharmacology. 1978;17(6):421–423. doi:10.1016/0028-3908(78)90018-7.
   PubMed Web of Science ®Google Scholar
• Jones RS, Roberts MH Effects of viloxazine on cortical neurone responses to monoamines and acetylcholine Paper presented at: Proceedings of the British Association for Psychopharmacology; March, 1977.
   Google Scholar
• Jones RS, Roberts MH Potentiation of monoamine responses of denervated cells by a noradrenaline uptake inhibitor (viloxazine) Paper presented at: Proceedings of the British Association for Psychopharmacology; March, 1978.
   Google Scholar
• Jones RS, Roberts MH Potentiation of responses to monoamines by antidepressants after destruction of monoamine afferents. Paper presented at: Proceedings of the British Association for Psychopharmacology; March, 1979.
   Google Scholar
• Devroye C, Cathala A, Di Marco B, et al. Central serotonin(2B) receptor blockade inhibits cocaine-induced hyperlocomotion independently of changes of subcortical dopamine outflow. Neuropharmacology. 2015;97:329–337. doi:10.1016/j.neuropharm.2015.06.012.
   Web of Science ®Google Scholar
• Cathala A, Devroye C, Maitre M, et al. Serotonin2C receptors modulate dopamine transmission in the nucleus accumbens independently of dopamine release: behavioral, neurochemical and molecular studies with cocaine. Addict Biol. 2015;20(3):445–457. doi:10.1111/adb.12137.
   Web of Science ®Google Scholar
• Shaw P, Stringaris A, Nigg J, Leibenluft E. Emotion dysregulation in attention deficit hyperactivity disorder. Am J Psychiatry. 2014;171(3):276–293. doi:10.1176/appi.ajp.2013.13070966.
   PubMed Web of Science ®Google Scholar
• Arnsten AF. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J Clin Psychiatry. 2006;67(Suppl 8):7–12.
   PubMed Web of Science ®Google Scholar
• Maletic V, Eramo A, Gwin K, Offord SJ, Duffy RA. The role of norepinephrine and its alpha-adrenergic receptors in the pathophysiology and treatment of major depressive disorder and schizophrenia: a systematic review. Front Psychiatry. 2017;8:42. doi:10.3389/fpsyt.2017.00042.
   PubMed Web of Science ®Google Scholar
• Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J Neurochem. 2010;114(1):259–270. doi:10.1111/j.1471-4159.2010.06750.x.
   PubMed Web of Science ®Google Scholar
• McCall JG, Siuda ER, Bhatti DL, et al. Locus coeruleus to basolateral amygdala noradrenergic projections promote anxiety-like behavior. Elife. 2017;6.
   Web of Science ®Google Scholar
• Cathala A, Devroye C, Drutel G, Revest JM, Artigas F, Spampinato U. Serotonin2B receptors in the rat dorsal raphe nucleus exert a GABA-mediated tonic inhibitory control on serotonin neurons. Exp Neurol. 2019;311:57–66. doi:10.1016/j.expneurol.2018.09.015.
   Web of Science ®Google Scholar
• Moreau JL, Bos M, Jenck F, Martin JR, Mortas P, Wichmann J. 5HT2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats. Eur Neuropsychopharmacol. 1996;6(3):169–175. doi:10.1016/0924-977X(96)00015-6.
   PubMed Web of Science ®Google Scholar
• Jenck F, Moreau JL, Berendsen HH, et al. Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur Neuropsychopharmacol. 1998;8(3):161–168. doi:10.1016/S0924-977X(97)00055-2.
   Web of Science ®Google Scholar
• Palacios JM, Pazos A, Hoyer D. A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment. Psychopharmacology (Berl). 2017;234(9–10):1395–1418.
   Web of Science ®Google Scholar
• Leggio GM, Cathala A, Moison D, Cunningham KA, Piazza PV, Spampinato U. Serotonin2C receptors in the medial prefrontal cortex facilitate cocaine-induced dopamine release in the rat nucleus accumbens. Neuropharmacology. 2009;56(2):507–513. doi:10.1016/j.neuropharm.2008.10.005.
   Web of Science ®Google Scholar
• Berg KA, Clarke WP, Cunningham KA, Spampinato U. Fine-tuning serotonin2c receptor function in the brain: molecular and functional implications. Neuropharmacology. 2008;55(6):969–976. doi:10.1016/j.neuropharm.2008.06.014.
   Web of Science ®Google Scholar
• Navailles S, Moison D, Cunningham KA, Spampinato U. Differential regulation of the mesoaccumbens dopamine circuit by serotonin2C receptors in the ventral tegmental area and the nucleus accumbens: an in vivo microdialysis study with cocaine. Neuropsychopharmacology. 2008;33(2):237–246. doi:10.1038/sj.npp.1301414.
   Web of Science ®Google Scholar
• Chagraoui A, Whitestone S, Baassiri L, Manem J, Di Giovanni G, De Deurwaerdere P. Neurochemical impact of the 5-HT2C receptor agonist WAY-163909 on monoamine tissue content in the rat brain. Neurochem Int. 2019;124:245–255. doi:10.1016/j.neuint.2019.01.019.
   Web of Science ®Google Scholar
• Whitestone S, Deurwaerdere P, Baassiri L, et al. Effect of the 5-HT2C receptor agonist WAY-163909 on serotonin and dopamine metabolism across the rat brain: a quantitative and qualitative neurochemical study. Int J Mol Sci. 2019;20:12. doi:10.3390/ijms20122925.
   Web of Science ®Google Scholar
• Ding YS, Naganawa M, Gallezot JD, et al. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: implications on treatment of depression and ADHD. Neuroimage. 2014;86:164–171. doi:10.1016/j.neuroimage.2013.08.001.
   PubMed Web of Science ®Google Scholar
• Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev. 2004;10(1):23–44. doi:10.1111/j.1527-3458.2004.tb00002.x.
   PubMedGoogle Scholar
• Curatolo P, Paloscia C, D’Agati E, Moavero R, Pasini A. The neurobiology of attention deficit/hyperactivity disorder. Eur J Paediatr Neurol. 2009;13(4):299–304. doi:10.1016/j.ejpn.2008.06.003.
   PubMed Web of Science ®Google Scholar
• Zhou FC, Sari Y, Zhang JK. Expression of serotonin transporter protein in developing rat brain. Brain Res Dev Brain Res. 2000;119(1):33–45. doi:10.1016/S0165-3806(99)00152-2.
   Google Scholar
• Chen X, Petit EI, Dobrenis K, Sze JY. Spatiotemporal SERT expression in cortical map development. Neurochem Int. 2016;98:129–137. doi:10.1016/j.neuint.2016.05.010.
   Web of Science ®Google Scholar
• Di Chiara G, Bassareo V, Fenu S, et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology. 2004;47(Suppl 1):227–241. doi:10.1016/j.neuropharm.2004.06.032.
   PubMed Web of Science ®Google Scholar
• Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present–a pharmacological and clinical perspective. J Psychopharmacol. 2013;27(6):479–496. doi:10.1177/0269881113482532.
   PubMed Web of Science ®Google Scholar
• Yanagita T, Wakasa Y, Kiyohara H. Drug dependence potential of viloxazine hydrochloride tested in rhesus monkeys. Pharmacol Biochem Behav. 1980;12(1):155–161. doi:10.1016/0091-3057(80)90430-X.
   PubMed Web of Science ®Google Scholar
• Cryan JF, Valentino RJ, Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev. 2005;29(4–5):547–569. doi:10.1016/j.neubiorev.2005.03.008.
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Drug Misuse Research Division, Health Research Board. Literature Review on the Relation Between Drug Use, Impaired Driving and Traffic Accidents (CT.97.EP.14). Lisbon: Portugal; 1999.
   Google Scholar
• Papoian T, Jagadeesh G, Saulnier M, et al. Regulatory forum review*: utility of in vitro secondary pharmacology data to assess risk of drug-induced valvular heart disease in humans: regulatory considerations. Toxicol Pathol. 2017;45(3):381–388. doi:10.1177/0192623317690609.
   PubMed Web of Science ®Google Scholar
• Bharti S, Rani N, Bhatia J, Arya DS. 5-HT2B receptor blockade attenuates beta-adrenergic receptor-stimulated myocardial remodeling in rats via inhibiting apoptosis: role of MAPKs and HSPs. Apoptosis. 2015;20(4):455–465. doi:10.1007/s10495-014-1083-z.
   Web of Science ®Google Scholar
• Janssen W, Schymura Y, Novoyatleva T, et al. 5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure. Biomed Res Int. 2015;2015:438403. doi:10.1155/2015/438403.
   Web of Science ®Google Scholar
• Canal CE, Morgan D, Felsing D, et al. A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses. J Pharmacol Exp Ther. 2014;349(2):310–318. doi:10.1124/jpet.113.212373.
   Web of Science ®Google Scholar
• Brody T. FDA’s Drug Review Process and the Package Label: Strategies for Writing Successful FDA Submissions. Academic Press; 2018:441–511.
   Google Scholar
• Maroteaux L, Ayme-Dietrich E, Aubertin-Kirch G, et al. New therapeutic opportunities for 5-HT2 receptor ligands. Pharmacol Ther. 2017;170:14–36. doi:10.1016/j.pharmthera.2016.10.008.
   Web of Science ®Google Scholar
• Herr N, Bode C, Duerschmied D. The effects of serotonin in immune cells. Front Cardiovasc Med. 2017;4:48. doi:10.3389/fcvm.2017.00048.
   PubMed Web of Science ®Google Scholar
• Krabbe G, Matyash V, Pannasch U, Mamer L, Boddeke HW, Kettenmann H. Activation of serotonin receptors promotes microglial injury-induced motility but attenuates phagocytic activity. Brain Behav Immun. 2012;26(3):419–428. doi:10.1016/j.bbi.2011.12.002.
   Web of Science ®Google Scholar
• Oades RD, Myint AM, Dauvermann MR, Schimmelmann BG, Schwarz MJ. Attention-deficit hyperactivity disorder (ADHD) and glial integrity: an exploration of associations of cytokines and kynurenine metabolites with symptoms and attention. Behav Brain Funct. 2010;6(1):32. doi:10.1186/1744-9081-6-32.
   PubMed Web of Science ®Google Scholar
• Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013;246:199–229. doi:10.1016/j.neuroscience.2013.04.060.
   PubMed Web of Science ®Google Scholar
• Brus R, Nowak P, Szkilnik R, Mikolajun U, Kostrzewa RM. Serotoninergics attenuate hyperlocomotor activity in rats. Potential new therapeutic strategy for hyperactivity. Neurotox Res. 2004;6(4):317–325. doi:10.1007/BF03033442.
   Web of Science ®Google Scholar
• Kostrzewa RM, Brus R, Kalbfleisch JH, Perry KW, Fuller RW. Proposed animal model of attention deficit hyperactivity disorder. Brain Res Bull. 1994;34(2):161–167. doi:10.1016/0361-9230(94)90013-2.
   Web of Science ®Google Scholar
• Whitney MS, Shemery AM, Yaw AM, Donovan LJ, Glass JD, Deneris ES. Adult brain serotonin deficiency causes hyperactivity, circadian disruption, and elimination of siestas. J Neurosci. 2016;36(38):9828–9842. doi:10.1523/JNEUROSCI.1469-16.2016.
   PubMed Web of Science ®Google Scholar
• Davids E, Zhang K, Kula NS, Tarazi FI, Baldessarini RJ. Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats. J Pharmacol Exp Ther. 2002;301(3):1097–1102. doi:10.1124/jpet.301.3.1097.
   Web of Science ®Google Scholar
• Yoo JH, Kim JI, Kim BN, Jeong B. Exploring characteristic features of attention-deficit/hyperactivity disorder: findings from multi-modal MRI and candidate genetic data. Brain Imaging Behav. 2019. doi:10.1007/s11682-019-00164-x.
   Web of Science ®Google Scholar
• Qureshi MNI, Oh J, Min B, Jo HJ, Multi-modal LB. Multi-measure, and multi-class discrimination of ADHD with hierarchical feature extraction and extreme learning machine using structural and functional brain MRI. Front Hum Neurosci. 2017;11:157.
   Web of Science ®Google Scholar
• Sudre G, Szekely E, Sharp W, Kasparek S, Shaw P. Multimodal mapping of the brain’s functional connectivity and the adult outcome of attention deficit hyperactivity disorder. Proc Natl Acad Sci U S A. 2017;114(44):11787–11792. doi:10.1073/pnas.1705229114.
   Web of Science ®Google Scholar
• Cao M, Shu N, Cao Q, Wang Y, He Y. Imaging functional and structural brain connectomics in attention-deficit/hyperactivity disorder. Mol Neurobiol. 2014;50(3):1111–1123. doi:10.1007/s12035-014-8685-x.
   PubMed Web of Science ®Google Scholar
• Conio B, Martino M, Magioncalda P, et al. Opposite effects of dopamine and serotonin on resting-state networks: review and implications for psychiatric disorders. Mol Psychiatry. 2020;25(1):82–93. doi:10.1038/s41380-019-0406-4.
   Web of Science ®Google Scholar
• Castellanos FX, Elia J, Kruesi MJ, et al. Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder. Psychiatry Res. 1994;52(3):305–316. doi:10.1016/0165-1781(94)90076-0.
   Web of Science ®Google Scholar
• Oades RD. Dopamine may be ‘hyper’ with respect to noradrenaline metabolism, but ‘hypo’ with respect to serotonin metabolism in children with attention-deficit hyperactivity disorder. Behav Brain Res. 2002;130(1–2):97–102. doi:10.1016/S0166-4328(01)00440-5.
   Web of Science ®Google Scholar
• Carhart-Harris RL, Nutt DJ. Serotonin and brain function: a tale of two receptors. J Psychopharmacol. 2017;31(9):1091–1120. doi:10.1177/0269881117725915.
   PubMed Web of Science ®Google Scholar
• Miyazaki KW, Miyazaki K, Doya K. Activation of dorsal raphe serotonin neurons is necessary for waiting for delayed rewards. J Neurosci. 2012;32(31):10451–10457. doi:10.1523/JNEUROSCI.0915-12.2012.
   Web of Science ®Google Scholar
• Miyazaki K, Miyazaki KW, Doya K. The role of serotonin in the regulation of patience and impulsivity. Mol Neurobiol. 2012;45(2):213–224. doi:10.1007/s12035-012-8232-6.
   Web of Science ®Google Scholar
• Cryan JF, Lucki I. Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors. J Pharmacol Exp Ther. 2000;295(3):1120–1126.
   PubMed Web of Science ®Google Scholar
• Del’Guidice T, Lemay F, Lemasson M, et al. Stimulation of 5-HT2C receptors improves cognitive deficits induced by human tryptophan hydroxylase 2 loss of function mutation. Neuropsychopharmacology. 2014;39(5):1125–1134. doi:10.1038/npp.2013.313.
   Web of Science ®Google Scholar